Something unexpected started happening to the neurosurgery team at Shanghai's Huashan Hospital. Their inbox began filling with requests from abroad — "basically two or three emails a week" — asking about clinical progress and whether treatment in Shanghai was possible.
Key takeaways
- First in the world: in March 2026, the NEO implantable brain–computer interface — whose registrational trial was led by Professor Mao Ying's team at Huashan Hospital — received marketing approval as the world's first approved implantable BCI Class III medical device.
- Evidence: 32 cases of clinical validation across 11 Chinese medical institutions, with a 100% clinical response rate for assisted grasping function.
- In use: the first prescription after approval and the first implant surgery were completed at Huashan in July 2026.
- Paid for: the system has been included in Shanghai's medical insurance coverage.
- Parallel programmes at the same hospital: ultrasound-mediated blood–brain barrier opening (5× drug concentration, 3-minute procedure) and real-time Mandarin decoding covering 394 syllables.
Three necessary cold showers
It compensates; it does not cure. The device's formal name is a "hand motor function compensation system." It does not repair damaged nerves. It routes around the break, translating the intention to move into action by an external device. The nerve remains severed.
The eligible population is narrow. It currently targets patients who have lost hand function, for example after spinal cord injury. Thirty-two cases is a small sample relative to the total population who might benefit.
It is surgery. Implantable means craniotomy, infection risk, long-term stability questions, and the open issue of whether electrode signal quality decays over time. Answers to those require five to ten years of follow-up.
One consequence of the overseas interest is uncomfortable: a significant share of the people writing in do not yet meet the criteria.
The two programmes that may reach ordinary patients sooner
Huashan disclosed two parallel lines of work that deserve separate attention.
Ultrasound BCI. Using a device called UltraBrainPad, the team uses ultrasound neuromodulation to open the blood–brain barrier, letting drugs into brain tissue — opening in about three minutes and closing safely afterwards. Early results show a fivefold increase in drug concentration reaching the brain, opening a path for treating aggressive tumours such as glioblastoma. It is in clinical trials.
Real-time Mandarin decoding. The team's work covers 394 Mandarin syllables, aiming to rebuild a communication channel for patients who have lost the ability to speak.
Both share a defining property: they serve a clearly defined, suffering population with no good alternative. That is usually where medical technology becomes real first.
If someone in your family is affected
- Ask "is it suitable" before "is it advanced." BCIs have strict indications. A full medical file and an assessment at a qualified centre beats a hundred online articles.
- Check two things: approval and reimbursement. Approval means it is legally accessible; insurance coverage means it is affordable. Both now exist for some products — and not for everything marketed under the "BCI" label.
- Be sceptical of consumer devices. Headbands and "focus trainers" sold to consumers are not the same thing as a clinical brain–computer interface. Spending several thousand on reassurance is worse than spending it on rehabilitation.
To judge whether a neurotechnology is real, ask three questions: does it have a regulatory approval number, is it reimbursed, and are its case numbers published? Those three answers are harder than any marketing claim.
Clinical and regulatory details as reported by Huashan Hospital and Chinese medical media, 2026.